QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer
NCT03022825Phase 2/3Active, not recruiting
- Lead sponsor
- ImmunityBio, Inc. (Industry)
- Enrollment
- 190 (actual)
- Start date
- 2 Jun 2017
- Primary completion
- 1 Oct 2024 (actual)
- Study completion
- 1 Mar 2029
- Last update posted
- 16 Oct 2025
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None
- Arms
- 1
Interventions
- N-803 and BCG Drug
- N-803 Drug
Conditions and primary outcome
- Bladder Cancer
Primary outcome
Complete Response (60 Months); Disease-Free Rate (12 Months)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
2 on PubMedProlonged Progression-Free Survival, Disease-Free Survival, and Cystectomy Avoidance With IL-15 Receptor Lymphocyte-Stimulating Agent NAI Plus Bacillus Calmette-Guérin in Bacillus Calmette-Guérin-Unresponsive Papillary-Only Nonmuscle-Invasive Bladder Cancer.
The Journal of urology · 2026 Jan
PubMed 40956664 (opens in a new tab)DOI 10.1097/JU.0000000000004782 (opens in a new tab)
N-803 Plus BCG Treatment for BCG-Naïve or -Unresponsive Non-Muscle Invasive Bladder Cancer: A Plain Language Review.
Future oncology (London, England) · 2024
PubMed 38953850 (opens in a new tab)DOI 10.1080/14796694.2024.2363744 (opens in a new tab)
Citations from PubMed, U.S. National Library of Medicine; abstracts are not stored. A publication lists this study’s NCT number and may be a review that cites many studies.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT03022825 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.